Anavex Life Sciences
AVXL
61 hedge funds and large institutions have $54.7M invested in Anavex Life Sciences in 2017 Q2 according to their latest regulatory filings, with 9 funds opening new positions, 25 increasing their positions, 10 reducing their positions, and 6 closing their positions.
150% more repeat investments, than reductions
Existing positions increased: 25 | Existing positions reduced: 10
50% more first-time investments, than exits
New positions opened: 9 | Existing positions closed: 6
5% more funds holding
Funds holding: 58 → 61 (+3)
2.08% more ownership
Funds ownership: 22.79% → 24.88% (+2.1%)
2% more capital invested
Capital invested by funds: $53.8M → $54.7M (+$957K)
0% more funds holding in top 10
Funds holding in top 10: 1 → 1 (0)
85% less call options, than puts
Call options by funds: $982K | Put options by funds: $6.49M
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
PWAM
Park West Asset Management
San Francisco,
California
|
+$1.97M |
| 2 |
Vanguard Group
Malvern,
Pennsylvania
|
+$763K |
| 3 |
BlackRock
New York
|
+$552K |
| 4 |
State Street
Boston,
Massachusetts
|
+$460K |
| 5 |
Northern Trust
Chicago,
Illinois
|
+$341K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
TCIM
TIAA CREF Investment Management
New York
|
-$171K |
| 2 |
HCM
Highbridge Capital Management
New York
|
-$121K |
| 3 |
JP Morgan Chase
New York
|
-$105K |
| 4 |
Citadel Advisors
Miami,
Florida
|
-$94.2K |
| 5 |
Barclays
London,
United Kingdom
|
-$72K |
AVXL Hedge Fund Activity: Q2 2017 in Review
61 of the 4,022 institutional investors tracked by Wall St. Rank reported a position in Anavex Life Sciences (AVXL) for Q2 2017, worth a combined $54.7M — up 1.8% from $53.8M a quarter earlier.
Buyers outnumbered sellers: 9 funds opened new AVXL positions and 6 closed out — a net gain of 3 holders — while 25 added to existing stakes and 10 trimmed.
The largest buyer was Park West Asset Management, adding an estimated $1.97M. The largest seller was TIAA CREF Investment Management, cutting an estimated $171K.
- 61 institutional investors held Anavex Life Sciences (AVXL) as of Q2 2017, up from 58 in Q1 2017.
- Funds reported $54.7M of Anavex Life Sciences stock for Q2 2017, up 1.8% quarter-over-quarter.
- 9 funds opened new Anavex Life Sciences positions in Q2 2017 and 6 closed out, a net change of +3 holders.
- The largest Anavex Life Sciences buyer in Q2 2017 was Park West Asset Management, an estimated $1.97M added.
- The largest Anavex Life Sciences seller in Q2 2017 was TIAA CREF Investment Management, an estimated $171K sold.
Based on aggregated 13F filings for Q2 2017.